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Thymic epithelial tumors (TET) are rare mediastinal neoplasms that can metastasize to
the pleural space (stage IVA). Complete surgical resection remains the backbone of ther-
apy for patients with early stage TET, however, the role of surgery in the management
of patients with stage IVA disease is not fully defined. Published reports in this regard
are mainly small, retrospective, and uncontrolled, with unclear inclusion criteria. Surgical
options to manage pleural disease include metastasectomy, extrapleural pneumonectomy,
and metastasectomy/pleurectomy combined with heated intrapleural chemotherapy. The
choice of the most appropriate surgical strategy needs to be individualized according to
the quantity and location of disease, the patient’s overall condition, as well as operator and
institutional expertise. In the majority of cases, metastasectomy of pleural implants will be
sufficient to achieve a complete resection.The available literature suggests that in selected
patients with stage IVA TET, delivery of neoadjuvant chemotherapy followed by complete
resection is a viable treatment option that can be associated with long-term survival.
Keywords: stage IVA thymoma, neoadjuvant therapy, surgery, metastasectomy, extrapleural pneumonectomy,
hyperthermic intrathoracic chemotherapy
INTRODUCTION
Thymic epithelial tumors (TET) are rare neoplasms, but they are
the most frequent anterior mediastinal tumors in adults. Accord-
ing to SEER (Surveillance, Epidemiology, and End Results) data,
the overall incidence of TET is 0.13 per 100,000 person-years (1).
Histologically, TET are biphasic tumors, comprised of epithelial
and lymphocytic components. The World Health Organization
system uses epithelial cellular atypia as well as the ratio of epithe-
lial cells to lymphocytes to classify TET into types A, AB, B1, B2,
B3, and carcinoma. TET are also classified using tumor stage. The
staging system that has gained worldwide acceptance is the one
proposed by Masaoka et al. (2) and subsequently modified by Koga
(3). Stage IVA TET is defined as disease which has spread to either
the pleural space or the pericardium but is not contiguous with
the primary tumor in the mediastinum. Although only approxi-
mately 7% of patients with TET will initially present with stage
IVA disease (4), the pleural space represents the most frequent site
of recurrence following resection (5).
THE RATIONALE FOR SURGICAL INTERVENTION IN STAGE
IVA TET
Surgical resection represents the mainstay of treatment for early
stage TET. The vast majority of patients with early stage (Masaoka
stage I and II) disease are cured by surgical resection alone. For
patients with stage III TET, the most consistent prognostic fac-
tor that has emerged is the ability to perform a complete surgical
resection with negative margins (R0 resection) (6–8). Based on
the importance of complete resection in patients with stage III
TET, a surgical approach has also been advocated for patients with
stage IVA disease as well, despite the absence of any published
controlled clinical trials. It is well accepted that surgical resection
for stage IVA disease appears to be safe. Many stage IVA patients
present in middle age and are otherwise healthy without signifi-
cant comorbid risk factors. As a result, the majority of published
studies that describe surgical resection for stage IVA TET report
no operative mortality (9–12).
The impact of surgical resection for stage IVA TET on onco-
logic outcome is less clear. Yano and colleagues (9) reported the
outcomes of 21 patients with stage IVA thymoma who underwent
multimodality treatment including neoadjuvant corticosteroid
therapy followed by surgical resection and adjuvant radiation ther-
apy. Seven additional patients did not undergo attempted resec-
tion. Patients that proceeded with surgical resection had 73.1%
5 year overall survival versus 0% for patients who did not. The
patients who were able to undergo complete macroscopic resec-
tion (n= 15) enjoyed a longer recurrence-free survival than those
with subtotal resection (n= 6) with a 3-year disease-free rate of
63.6% compared to 20.8%, respectively (p= 0.009). There was
no mortality at 30 days, and perioperative morbidity occurred in
four (19%) patients. In another study of 23 patients with inva-
sive thymoma published by Froudarakis and colleagues (13), the
authors analyzed outcomes based on two treatment paradigms:
surgical resection± chemo(radio)therapy (n= 11), or radiother-
apy± chemotherapy (n= 12). Patients in the operative group
experienced longer overall survival than those in the non-operative
group (p< 0.0001).
The importance of complete resection has also been reported
in patients with stage IVA TET. In this regard, Rena and col-
leagues (14) analyzed the outcomes of 18 patients with Stage
IVA thymoma, and demonstrated that outcome was poor in
patients with incomplete resection. After a mean followup period
of 82 months, disease specific 10 year survival was 52% following
complete macroscopic resection compared to 0% after incomplete
resection (p= 0.048). Similar outcomes were reported by Regnard
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and colleagues (7) after mean of 8 years of followup. For patients
with stage IVA TET who underwent R0 resection (n= 12), the 5-
year overall survival was 64%, compared to 34% for the patients
(n= 6) who were incompletely resected.
In summary, surgical resection for stage IVA TET appears to be
safe, with very low operative mortality reported. Although some
studies report enhanced survival after R0 resection relative to
patients who do not undergo resection, these reports are small,
mainly retrospective, and subject to selection bias. Without con-
trolled clinical trials, it remains unclear if the enhanced oncologic
outcome achieved with surgery is due to the resection itself, or
merely a reflection of probable lower tumor burden in the patients
selected for a surgical approach.
SURGICAL APPROACHES FOR PATIENTS WITH STAGE IVA
THYMIC TUMORS
For patients with stage IVA TET, surgical options to manage
the pleural disease include metastasectomy, extrapleural pneu-
monectomy (EPP), and metastasectomy/pleurectomy combined
with heated intrapleural chemotherapy. The choice of the most
appropriate surgical strategy needs to be individualized accord-
ing to the quantity and location of disease, as well as operator
and institutional expertise. In many situations, the surgeon does
not know the extent of resection that will need to be performed
until the chest is explored. No prospective clinical trials have been
published that examine differences in outcome according to the
surgical approach.
METASTASECTOMY
The most common surgical approach for TET that has metasta-
sized to the pleura is localized excision of all visible intrathoracic
disease (metastasectomy). When patients initially present with
stage IVA disease radiographically and the primary tumor has
not yet been resected, the incision must be planned in order
to accommodate exploration of the hemithorax containing the
pleural disease. In most circumstances, a median sternotomy alone
is not adequate for pleural exploration, and oftentimes the com-
bination of a partial median sternotomy with an anterior thora-
cotomy (hemiclamshell) facilitates exposure of the pleural cavity.
In the uncommon circumstance where both pleural cavities need
to be explored, bilateral anterior thoracotomies combined with a
transverse sternotomy (clamshell) may be required for exposure.
Since the pleural space is the most common site of recurrence
following initial resection of TET, it is not uncommon to also
address pleural disease in the absence of a mediastinal lesion. In
these cases, the pleural space is best approached using a standard,
posterolateral thoracotomy. This incision permits visualization of
the entire hemithorax, allowing the surgeon adequate exposure
to employ a wide variety of resection techniques. Although video
assisted thoracic surgery (VATS) has gained acceptance for the
management of other intrathoracic disease states, including early
stage TET (15, 16), its use for advanced lesions is limited due to
the need to thoroughly explore the entire pleural cavity and resect
multiple lesions in many cases.
Once the chest has been explored, the surgeon tailors the oper-
ation according to the number, size, and location of the metastatic
lesions. Deposits that are confined to the parietal pleura are usually
easily resected with a margin of normal pleura. Visceral pleural
deposits can either be removed using electrocautery or, if larger,
by performing a wedge resection of the lung with an automatic
stapler. In the unusual circumstance where a large visceral pleural
lesion is invading the lung, an anatomic pulmonary resection (e.g.,
lobectomy) may be required. Reported results with this approach
show perioperative mortality of 0% and morbidity up to 39%
(9–12, 14).
EXTRAPLEURAL PNEUMONECTOMY
Occasionally, the surgeon may explore the chest of a patient with
the intent of performing metastasectomy, only to find extensive,
diffuse visceral, and parietal pleural implants which are too numer-
ous to remove individually. In this circumstance, a decision must
be made regarding the performance of EPP. EPP involves resection
of the entire lung in addition to its surrounding pleural envelope,
thereby removing all pleural tissue. This operation is performed
through a posterolateral thoracotomy, and involves resection and
reconstruction of the hemidiaphragm as well. Usually considered
as a “last resort,” EPP has been reported to be associated with long-
term survival in patients with stage IVA TET (17–19). A potential
benefit of the performance of EPP is that higher doses of postoper-
ative radiotherapy can be administered to the involved hemithorax
with less toxicity than if the lung remained in situ (20, 21).
The largest series of EPP for thymic tumors was published by
Fabre and colleagues (17). The authors analyzed the outcome of
17 patients that underwent EPP for Masaoka stage IVA thymoma
over a period of 39 years. Eight patients had recurrent thymoma
and nine patients presented de novo with stage IVA disease. All
patients underwent EPP and an R0 resection was achieved in 11
(65%). Five patients (29.4%) underwent adjuvant therapy con-
sisting of chemotherapy (n= 2), radiotherapy (n= 1), or both
(n= 2). With a median followup of 59 months, the 5- and 10-year
overall survival was 60 and 30%, respectively. During the followup
period, two patients experienced recurrence. Perioperatively, there
were no deaths, but the 30-day mortality was 17.6%. In addition,
eight patients (47%) experienced major postoperative complica-
tions, including four with postpneumonectomy bronchopleural
fistula (23%). In another report, Wright and colleagues described
five patients who underwent EPP for stage IVA thymoma and
demonstrated no operative mortality with a single patient having
a major complication. The overall 10 year survival was 50% (18).
In summary, radical surgery in the form of EPP represents a “last
resort” option for patients with stage IVA TET, but surgical mor-
tality and morbidity are significant and the oncologic benefit is
unproven.
INTRAOPERATIVE, HYPERTHERMIC, INTRATHORACIC CHEMOTHERAPY
A relatively new surgical approach involves resection of pleural
disease with administration of intraoperative hyperthermic,
intrathoracic chemotherapy (HITHOC). This strategy has been
suggested for stage IVA TET as early as 2001. Using a standard
roller pump and heat exchanger, perfusion of the pleural space
is initiated without the chemotherapeutic agents at the rate of
1,000–2,000 ml/min with an inflow temperature of 42°C. Once the
outflow temperature has stabilized, the chemotherapeutic agent(s)
is added and perfusion is performed over a usual period of 60 min.
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Refaely and colleagues (22) published the outcome of 15
patients who underwent resection and hyperthermic pleural per-
fusion with chemotherapy. The procedure included resection with
or without pleurectomy, with a solitary patient undergoing EPP.
All patients received intraoperative hyperthermic intrapleural cis-
platin. During perfusion, the intrapleural temperature reached
40.3–43°C. There was no operative mortality, but complications
consisted of significant bleeding (n= 2), fever (n= 2), and air leak
(n= 1). Excluding patients with thymic carcinoma (n= 5), the 3-
and 5-year overall survival rates were 90 and 70%, respectively,
with a median followup of 34 months. The authors concluded
that surgical resection with HITHOC is safe and seems to offer
good local control for patients with stage IVA TET.
This approach has enjoyed a resurgence of interest in recent
years (23–26). Several small reports demonstrate no mortality
within 30 days, with overall survival rates of 67–89% without evi-
dence of recurrence. However, the length of followup was too
short in these studies (18.8–29 months), given that TET may take
many years to recur. The largest study was conducted by Yellin and
colleagues (26), which evaluated 35 patients. Seventeen patients
presented with de novo stage IVA disease, 14 with pleural recur-
rence after a previous resection, while four had thymic carcinoma.
There was no systemic toxicity reported with HITHOC, the mor-
tality at 90 days was 2.5%, and major morbidity occurred in four
patients (11.4%). The 5- and 10-year overall survival was 81 and
73%, respectively, for de novo thymomas, but this decreased to
67 and 56% for patients who presented with recurrent tumors.
Patients with thymic carcinoma had the worst outcome, with no
patients surviving 5 years. Progression-free survival was higher in
patients who were deemed to have undergone an R0 resection
compared to incompletely resected patients (p< 0.001).
PHOTODYNAMIC THERAPY
The use of the photodynamic therapy (PDT) can potentially add
another dimension to treatment of patients with stage IVA TET.
This modality has been described in conjunction with radical
pleurectomy for patients with pleural mesothelioma (27). How-
ever, to date, there are no published reports that evaluated the use
of intraoperative PDT for pleural disease in patients with stage
IVA TET. Further investigation is needed to see if PDT has a role
in treatment of these patients.
NEOADJUVANT THERAPY AND STAGE IVA THYMIC TUMORS
The use of neoadjuvant chemotherapy followed by surgical resec-
tion for thoracic malignancies was initially popularized in patients
with locally advanced lung cancer beginning in the 1980s. This
concept was then applied to locally advanced TET, with the first
study in stage III TET reported in 1991 (28). The rationale behind
using neoadjuvant therapy in locally advanced TET patients is that
TET are chemoresponsive tumors and the prospect of enhancing
resectability using preoperative treatment is attractive, since the
ability to perform an R0 resection is a strong prognostic factor.
The use of neoadjuvant therapy for patients with stage IVA TET
has subsequently emerged as a viable treatment strategy, and has
been reported in several, mainly retrospective studies (Table 1).
Of note, a formal, prospective, phase II clinical trial that eval-
uated the impact of induction therapy in 22 patients with stage
III and IVA thymomas (stage IVA n= 10) was published by Kim
and colleagues (12). Patients underwent neoadjuvant chemother-
apy consisting of cyclophosphamide, doxorubicin, cisplatin, and
prednisone, followed by surgical resection, radiation therapy and
consolidation chemotherapy. Nineteen of 22 patients completed
the planned therapy. In the entire cohort, induction chemother-
apy produced a major radiographic response in 17 patients (77%),
and 16 patients (76%) were able to achieve an R0 resection. With
a median followup of 50.3 months, the overall survival rate was
95% at 5 years and 79% at 7 years. The progression-free survival
was 77% at 5 years and 77% at 7 years (12).
As shown in Table 1, the high radiographic response rates
to neoadjuvant therapy reflect the chemoresponsiveness of these
tumors. In addition, the rate of R0 resection in patients with stage
IVA TET following neoadjuvant therapy is in the range of 58–
100%. These figures compare favorably to reports of resection
without the use of neoadjuvant therapy in patients with stage IVA
TET. Studies with surgical resection as a primary therapy followed
by adjuvant therapy show the rate of complete resection to be
lower (43–63%), with 5 and 10 year overall survival rates in the
range of 30–47% (7, 32, 33).
A small number of non-randomized studies have attempted
to compare the outcomes of patients with stage IVA TET who
undergo treatment with neoadjuvant therapy followed by surgi-
cal resection to those who were operated upon primarily. Luc-
chi and colleagues reported 36 patients with stage III and IVA
TET who underwent multimodality treatment with neoadjuvant
chemotherapy, surgical resection, and postoperative radiotherapy.
This group was compared to 20 patients who were treated by
primary surgery and postoperative chemo(radio)therapy (10). In
the entire cohort, the radiographic response rate to neoadjuvant
chemotherapy was 67%. Stage IVA patients who received neoadju-
vant therapy had an R0 resection rate of 72.7% (8 of 11), compared
to 40% (2 of 5) in the patients who underwent primary resec-
tion. Neoadjuvant therapy also improved survival significantly
(p< 0.02).
Cardillo and colleagues also compared the use of neoadju-
vant therapy followed by surgical resection to primary resection
in patients with stage III and stage IVA TET. Unfortunately, the
data were not analyzed individually according to tumor stage.
After a median followup period of 77 months (8), the 10-year
overall survival rate in the group of patients who received neoad-
juvant chemotherapy was 57.9%, compared to 38.1% in patients
who underwent primary surgical resection. Multivariate analysis
confirmed that R0 resection and induction chemotherapy were
statistically significant independent predictors of survival.
SUMMARY
The role of surgical resection in the management of patients
with stage IVA TET is not fully defined. Published reports are
mainly small, retrospective, and uncontrolled, with unclear inclu-
sion criteria. This makes it difficult to separate any potentially
positive effects of surgical intervention from other important vari-
ables, including tumor burden. Further, the published literature
frequently analyzes stages III and IVA collectively as advanced
disease. Despite this, the available literature suggests that in
selected patients with stage IVA TET, delivery of neoadjuvant
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Table 1 | Outcome of patients with stage IVATET treated with neoadjuvant therapy followed by surgical resection.
Reference n Induction
response (%)
Complete
resection (%)
Median followup
(months)
Recurrence
rate (%)b
5-Year overall
survival (%)
10-Year overall
survival (%)
Rea et al. (34)a 16 100 – – – 70d –
Venuta et al. (29) 13 100 76.9 53 10 – 68e
Refaely et al. (22) 15 – 66.7 34 30 70 –
Kim et al. (12)a 22 77 76 50 – 95 79f
Lucchi (10) 11 66.7a 72.7 – – – 45.7
Lucchi et al. (30) 10 73.3a 76.7a 94 – – 76.4
Huang et al. (11) 18 67 67 22 25 78 65
Yano et al. (9) 21 – 71 – – 73.1 37.6
Cardillo et al. (8)a 31 75.6 58.1 77 – – 57.9
Okereke et al. (31) 15 – 100 57c – 88 50
Rena et al. (14) 18 86 62.5 95c 50 85 53
aIncludes patients with Masaoka stages III and IVA thymoma.
bPatients that underwent complete resection.
cMean followup.
d3-Year followup.
e8-Year followup.
f7-Year followup.
chemotherapy followed by R0 resection is a viable treatment
option that is associated with long-term survival. The extent of
surgical intervention should be based on the patient’s overall
condition and the extent of pleural disease. In the majority of
cases, metastasectomy of pleural implants will be sufficient to
achieve an R0 resection. In highly selected patients with extensive
pleural deposits, EPP remains an option, but significant post-
operative morbidity and mortality need to be considered. The
role of HITHOC remains undefined, but worthy of further inves-
tigation. Given the rarity of stage IVA TET, it will be difficult
to answer questions regarding the management of this disease
without well-designed, multi-institutional clinical trials in order
to achieve significant accrual. The formal organization of physi-
cians interested in TET by the International Thymic Malignancy
Interest Group (ITMIG) will help in this regard, allowing clin-
ical trial accrual to be expanded to multiple institutions and
countries.
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